Inovio Pharma jumps after US FDA approves rare disease therapy
INO•Inovio Pharmaceuticals shares rose 293.4% to $2.36 in extended trading after the US FDA approved its Voceryq therapy for recurrent respiratory papillomatosis.
1. FDA approves therapy
The US FDA approved Inovio Pharmaceuticals’ Voceryq to treat recurrent respiratory papillomatosis, a condition that causes growths in the airways and often requires repeated surgeries. Inovio plans to commercialize the therapy on its own in the US and is working with Syneos Health to support the launch.
